Pharmacokinetics and Safety of BI 695502 in Healthy Subjects: a Randomized, Single-blind, Single-dose, Parallel-arm, Active-comparator Clinical Phase I Study
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2017
At a glance
- Drugs Bevacizumab (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Pharmacokinetics
- Acronyms INVICTAN-1
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharmaceuticals
- 01 Aug 2017 Primary endpoint of AUC of the analyte in plasma from time zero extrapolated to infinity has been met, according to results published in the Expert Opinion on Investigational Drugs.
- 01 Aug 2017 Results published in the Expert Opinion on Investigational Drugs
- 01 Aug 2017 Status changed from recruiting to discontinued according to results published in the Expert Opinion on Investigational Drugs.